Key result
Rosuvastatin slows carotid intima-media thickness progression by ~0.019 mm over 96 weeks in HIV.
RCT (n=147)
Double-blind
Randomized
Answers are grounded in this paper and cite their sources.
OBJECTIVE: To determine the effect of statins on the progression of subclinical atherosclerosis in a population of HIV-infected adults on antiretroviral therapy. DESIGN: Double-blind, randomized clinical trial. METHODS: Stopping Atherosclerosis and Treating Unhealthy Bone with RosuvastatiN in HIV infection was a 96-week double-blind, randomized clinical trial of 10 mg daily rosuvastatin (n = 72) vs. placebo (n = 75) in a population of HIV-infected subjects on stable antiretroviral therapy with LDL-cholesterol 130 mg/dl or less (≤3.36 mmol/l) and evidence of heightened T-cell activation (CD8CD38HLA-DR ≥19%) or increased inflammation [high sensitivity C-reactive protein ≥2 mg/l (≥19 mmol/l)]. Change in common carotid artery intima-media thickness (IMT) (CCA-IMT) was the primary outcome. Secondary outcomes were changes in LDL and coronary artery calcium. RESULTS: Median (Q1, Q3) age was 46 (40, 53) years; 78% were man and 68% African-American; 49% were on a protease inhibitor. Mean (95% confidence interval) change in LDL was -21 (-27 to -15) mg/dl [-0.54 (-0.70 to -0.39) mmol/l] in the rosuvastatin arm. In a multivariable linear mixed-effects model, assignment to statin was associated with 0.019 mm (95% confidence interval: 0.002-0.037 mm) less progression of CCA-IMT over 96 weeks. We did not find substantial effect modification by level of inflammation or immune activation biomarkers, except for a borderline statistically significant interaction for soluble vascular cell adhesion molecule (P = 0.065). There was no difference in coronary artery calcium change (P = 0.61). CONCLUSION: Rosuvastatin effectively lowers LDL and appears to substantially slow progression of CCA-IMT in patients with treated HIV infection. Future study is needed to determine whether subjects with higher levels of inflammation or immune activation derive greater cardiovascular benefit from statin therapy.
No takes yet. Share an insight, caveat, or question.
Longenecker et al. (2016) conducted an RCT in Treated HIV infection with subclinical atherosclerosis (n=147). Rosuvastatin vs. Placebo was evaluated on Change in common carotid artery intima-media thickness (CCA-IMT) (MD 0.019 mm, 95% CI 0.002-0.037). Rosuvastatin daily was associated with 0.019 mm less progression of common carotid artery intima-media thickness over 96 weeks compared to placebo in treated HIV.
Synapse has enriched 10 related papers. Consider them for comparative context: